Monte Rosa Therapeutics Is A Clinical Stage Biotechnology Company Based In Bostonmassachusettsthe Company Focuses On Developing Novel Molecular Glue Degradermgdmedicines Aimed At Treating Serious Diseasesparticularly In Oncologyautoimmuneand Inflammatory Conditionsmonte Rosa Utilizes A Drug Discovery Platform That Harnesses The Body S Natural Mechanisms To Selectively Eliminate Relevant Proteins Through Specific Protein Ubiquitination And Proteasomal Degradationtheir Queena C Platform Integrates Proprietary Mgd Libraries With Advanced Techniques In Proteomicsstructural Biologyaiand Computational Chemistry To Identify Protein Targets And Design Selective Degraders Efficiently The Company Has Several Candidates In Its Development Pipelineincluding Mrt 2359An Oral Gspt1 Degrader For Myc Driven Tumorsand Mrt 6160The First Mgd For Immunologydeveloped In Partnership With Novartismonte Rosa Also Collaborates With Roche To Create Innovative Treatments Across Various Indicationspublicly Traded On Nasdaq Under The Ticker Gluemonte Rosa Therapeutics Is Committed To Advancing Its Research Through Strategic Partnerships And A Dedicated Team Of Experts
No conferences found for this company.
| Company Name | Monte Rosa Sa |
| Country |
Nicaragua
|
| Address | Bolonia Antiguo Hosp El Retiro 1c Al N 1c Al E 25vrs Al N Managua Nicaragua |
| Telephone | Login to View |
| Login to View |
